Drugs Made In America Acquisition II Secures Bridge Financing

Drugs Made In America Acquisition II Corp. ( (DMII) ) has shared an announcement.

On March 11, 2026, Drugs Made In America Acquisition II Corp. issued a $150,000 unsecured convertible bridge note to Alpha Multi Family Office as the first tranche of a planned $1.4 million convertible notes financing. The bridge note creates a direct financial obligation for the SPAC and provides initial liquidity while longer-term financing terms are finalized.

The funding follows a March 5, 2026 letter of intent and a March 9, 2026 addendum between the company and the investor, which set the total contemplated financing at $1.4 million, with the remaining $1.25 million subject to a definitive convertible note purchase agreement. Under the amended terms, the parties expect an aggregate $400,000 to be disbursed to the company on or before March 30, 2026, potentially strengthening its capital position as it pursues prospective transactions and corporate objectives.

More about Drugs Made In America Acquisition II Corp.

Drugs Made In America Acquisition II Corp. operates as a special purpose acquisition company (SPAC), formed to raise capital and pursue merger or acquisition opportunities, typically in sectors aligned with its mandate to support U.S.-based pharmaceutical and healthcare-related businesses. The company focuses on deploying investor capital through structured financing arrangements to facilitate future business combinations or strategic transactions.

Average Trading Volume: 127,179

Current Market Cap: $653.1M

For detailed information about DMII stock, go to TipRanks’ Stock Analysis page.